Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNO in Symptomatic PAH (INOvation-1)
NCT02725372Phase 3Terminated
- Sponsor
- Bellerophon Therapeutics
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 18
01
Overview
A Phase 3 trial of nitric oxide in pulmonary arterial hypertension (PAH), sponsored by Bellerophon Therapeutics. Started Apr 2016; status: terminated.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02725372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725372.